Meagan B. Ryan

Clinical Acquired Resistance to KRASG12C Inhibition through a Novel KRAS Switch-II Pocket Mutation and Polyclonal Alterations Converging on RAS–MAPK Reactivation

Noritaka Tanaka, Chendi Li, Meagan B. Ryan et al. · Cancer Discovery · 2021 · 475 citations · Full text

KRASG12C-independent feedback activation of wild-type RAS constrains KRASG12C inhibitor efficacy

Meagan B. Ryan, Oluwadara Coker, Alexey V. Sorokin et al. · Cell Reports · 2022 · 138 citations · Full text

Signal Transduction, Functional Selectivity, Medicine +7

Targeting RAS -mutant Cancers: Is ERK the Key?

Meagan B. Ryan, Channing J. Der, Andrea Wang‐Gillam et al. · Trends in cancer · 2015 · 133 citations · Full text

Oncology, Medicine, Ras -Mutant Cancers +6

GSK-3α Promotes Oncogenic KRAS Function in Pancreatic Cancer via TAK1–TAB Stabilization and Regulation of Noncanonical NF-κB

Deepali Bang, Willie Wilson, Meagan B. Ryan et al. · Cancer Discovery · 2013 · 114 citations · Full text

Cancer Biology, Tumor Biology, Signaling Pathway +18

Extracellular Signal-regulated Kinase (ERK) Phosphorylates Histone Deacetylase 6 (HDAC6) at Serine 1035 to Stimulate Cell Migration

Kendra A. Williams, Mu Zhang, Shengyan Xiang et al. · Journal of Biological Chemistry · 2013 · 109 citations · Full text

Chromatin, Signal Transduction, Signaling Pathway +12